136 related articles for article (PubMed ID: 33433405)
1. MCM3 proliferative index is worthier over Ki-67 in the characterization of salivary gland tumors.
Raja R; Shetty DC; Chandrakanta ; Juneja S; Tandon A; Gulati N
Indian J Pathol Microbiol; 2021; 64(1):22-27. PubMed ID: 33433405
[TBL] [Abstract][Full Text] [Related]
2. MCM3 as a novel diagnostic marker in benign and malignant salivary gland tumors.
Ashkavandi ZJ; Najvani AD; Tadbir AA; Pardis S; Ranjbar MA; Ashraf MJ
Asian Pac J Cancer Prev; 2013; 14(6):3479-82. PubMed ID: 23886132
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical Detection of Proliferative Marker Ki-67 in Benign and Malignant Salivary Gland Tumors.
Bussari S; Ganvir SM; Sarode M; Jeergal PA; Deshmukh A; Srivastava H
J Contemp Dent Pract; 2018 Apr; 19(4):375-383. PubMed ID: 29728539
[No Abstract] [Full Text] [Related]
4. Expression of p53 and selected proliferative markers (Ki-67, MCM3, PCNA, and topoisomerase IIα) in borderline ovarian tumors: Correlation with clinicopathological features.
Ciepliński K; Jóźwik M; Semczuk-Sikora A; Gogacz M; Lewkowicz D; Ignatov A; Semczuk A
Histol Histopathol; 2018 Feb; 33(2):171-179. PubMed ID: 28493257
[TBL] [Abstract][Full Text] [Related]
5. P53 and Ki-67 antigen expression in small oral biopsy specimens of salivary gland tumors.
Lazzaro B; Cleveland D
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2000 May; 89(5):613-7. PubMed ID: 10807720
[TBL] [Abstract][Full Text] [Related]
6. Benign and malignant oncocytoma of the salivary glands with an immunohistochemical evaluation of Ki-67.
Ito K; Tsukuda M; Kawabe R; Nakagawa C; Matsushita K; Kubota A; Furukawa M; Kameda Y; Ito T
ORL J Otorhinolaryngol Relat Spec; 2000; 62(6):338-41. PubMed ID: 11054019
[TBL] [Abstract][Full Text] [Related]
7. MCM3 could be a better marker than Ki-67 for evaluation of dysplastic oral lesions: an immunohistochemical study.
Lameira AG; Pontes FS; Guimarães DM; Alves AC; de Jesus AS; Pontes HA; Pinto Ddos S
J Oral Pathol Med; 2014 Jul; 43(6):427-34. PubMed ID: 24456424
[TBL] [Abstract][Full Text] [Related]
8. Salivary gland malignant myoepithelioma: a clinicopathologic and immunohistochemical study of ten cases.
Nagao T; Sugano I; Ishida Y; Tajima Y; Matsuzaki O; Konno A; Kondo Y; Nagao K
Cancer; 1998 Oct; 83(7):1292-9. PubMed ID: 9762928
[TBL] [Abstract][Full Text] [Related]
9. Comparison between immunohistochemical expression of Ki-67 and MCM-3 in major salivary gland epithelial tumors in children and adolescents. Preliminary study.
Zieliński R; Kobos J; Zakrzewska A
Pol J Pathol; 2016; 67(4):351-356. PubMed ID: 28547962
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometric analysis of DNA content and Ki-67-positive fractions in the diagnosis of salivary gland tumors.
Horii A; Yoshida J; Sakai M; Okamoto S; Kubo T
Eur Arch Otorhinolaryngol; 1998; 255(5):265-8. PubMed ID: 9638470
[TBL] [Abstract][Full Text] [Related]
11. MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.
Kang EY; Millstein J; Popovic G; Meagher NS; Bolithon A; Talhouk A; Chiu DS; Anglesio MS; Leung B; Tang K; Lambie N; Pavanello M; Da-Anoy A; Lambrechts D; Loverix L; Olbrecht S; Bisinotto C; Garcia-Donas J; Ruiz-Llorente S; Yagüe-Fernandez M; Edwards RP; Elishaev E; Olawaiye A; Taylor S; Ataseven B; du Bois A; Harter P; Lester J; Høgdall CK; Armasu SM; Huang Y; Vierkant RA; Wang C; Winham SJ; Heublein S; Kommoss FKF; Cramer DW; Sasamoto N; van-Wagensveld L; Lycke M; Mateoiu C; Joseph J; Pike MC; Odunsi K; Tseng CC; Pearce CL; Bilic S; Conrads TP; Hartmann A; Hein A; Jones ME; Leung Y; Beckmann MW; Ruebner M; Schoemaker MJ; Terry KL; El-Bahrawy MA; Coulson P; Etter JL; LaVigne-Mager K; Andress J; Grube M; Fischer A; Neudeck N; Robertson G; Farrell R; Barlow E; Quinn C; Hettiaratchi A; Casablanca Y; Erber R; Stewart CJR; Tan A; Yu Y; Boros J; Brand AH; Harnett PR; Kennedy CJ; Nevins N; Morgan T; Fasching PA; Vergote I; Swerdlow AJ; Candido Dos Reis FJ; Maxwell GL; Neuhausen SL; Barquin-Garcia A; Modugno F; Moysich KB; Crowe PJ; Hirasawa A; Heitz F; Karlan BY; Goode EL; Sinn P; Horlings HM; Høgdall E; Sundfeldt K; Kommoss S; Staebler A; Wu AH; Cohen PA; DeFazio A; Lee CH; Steed H; Le ND; Gayther SA; Lawrenson K; Pharoah PDP; Konecny G; Cook LS; Ramus SJ; Kelemen LE; Köbel M
Virchows Arch; 2022 Apr; 480(4):855-871. PubMed ID: 34782936
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling revealed MCM3 to be a better marker than Ki67 in prognosis of invasive ductal breast carcinoma patients.
Zhao Y; Wang Y; Zhu F; Zhang J; Ma X; Zhang D
Clin Exp Med; 2020 May; 20(2):249-259. PubMed ID: 31980982
[TBL] [Abstract][Full Text] [Related]
13. The sonic hedgehog signaling pathway contributes to the development of salivary gland neoplasms regardless of perineural infiltration.
Vidal MT; Lourenço SV; Soares FA; Gurgel CA; Studart EJ; Valverde Lde F; Araújo IB; Ramos EA; Xavier FC; Dos Santos JN
Tumour Biol; 2016 Jul; 37(7):9587-601. PubMed ID: 26790448
[TBL] [Abstract][Full Text] [Related]
14. Caveolin-1 overexpression in benign and malignant salivary gland tumors.
Jaafari-Ashkavandi Z; Ashraf MJ; Nazhvani AD; Azizi Z
Tumour Biol; 2016 Feb; 37(2):1863-9. PubMed ID: 26323261
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of Ki-67 in salivary gland carcinomas.
Larsen SR; Bjørndal K; Godballe C; Krogdahl A
J Oral Pathol Med; 2012 Sep; 41(8):598-602. PubMed ID: 22530699
[TBL] [Abstract][Full Text] [Related]
16. In vitro study on the effect of doxorubicin on the proliferation markers MCM3 and Ki-67.
Etemad-Moghadam S; Fouladdel S; Azizi E; Alaeddini M
J BUON; 2013; 18(4):1062-8. PubMed ID: 24344040
[TBL] [Abstract][Full Text] [Related]
17. MCM3: A Novel Proliferation Marker in Oral Squamous Cell Carcinoma.
Valverde LF; de Freitas RD; Pereira TA; de Resende MF; Agra IMG; Dos Santos JN; Dos Reis MG; Sales CBS; Gurgel Rocha CA
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):120-125. PubMed ID: 27258565
[TBL] [Abstract][Full Text] [Related]
18. Basal cell adenocarcinoma of the salivary glands: comparison with basal cell adenoma through assessment of cell proliferation, apoptosis, and expression of p53 and bcl-2.
Nagao T; Sugano I; Ishida Y; Hasegawa M; Matsuzaki O; Konno A; Kondo Y; Nagao K
Cancer; 1998 Feb; 82(3):439-47. PubMed ID: 9452259
[TBL] [Abstract][Full Text] [Related]
19. Telomerase activity in oral and maxillofacial tumors.
Liao J; Mitsuyasu T; Yamane K; Ohishi M
Oral Oncol; 2000 Jul; 36(4):347-52. PubMed ID: 10899673
[TBL] [Abstract][Full Text] [Related]
20. Frequency and Histopathology by Site, Major Pathologies, Symptoms and Signs of Salivary Gland Neoplasms.
Bradley PJ
Adv Otorhinolaryngol; 2016; 78():9-16. PubMed ID: 27092790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
